BRAF Activation and Invasive Prostate Cancer
Author Information
Author(s): Jeong Joseph H., Wang Zhenxiong, Guimaraes Alexander S., Ouyang Xuesong, Figueiredo Jose L., Ding Zhihu, Jiang Shan, Guney Isil, Kang Gyeong Hoon, Shin Eyoung, Hahn William C., Loda Massimo F., Abate-Shen Cory, Weissleder Ralph, Chin Lynda
Primary Institution: Dana-Farber Cancer Institute, Harvard Medical School
Hypothesis
Does BRAF activation initiate prostate adenocarcinoma without being necessary for its maintenance?
Conclusion
BRAF activation can initiate invasive prostate adenocarcinoma but is not required for its maintenance.
Supporting Evidence
- BRAF activation leads to increased proliferation in prostate cells.
- Genetically engineered mice developed prostate tumors with high penetrance.
- Post-castration tumors remained viable despite reduced growth rates.
Takeaway
This study shows that a specific mutation can start prostate cancer, but once it starts, the mutation isn't needed to keep the cancer growing.
Methodology
The study used genetically engineered mouse models to analyze the effects of BRAF activation on prostate cancer development.
Limitations
The study primarily focuses on a specific genetic model and may not fully represent all prostate cancer cases.
Participant Demographics
The study involved genetically engineered mice, specifically targeting the prostate epithelium.
Statistical Information
P-Value
0.00035
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website